Search

Your search keyword '"Wehling M"' showing total 973 results
Start Over Author "Wehling M"
973 results on '"Wehling M"'

1. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research

Author

Seppala, L. J., van der Velde, N., Masud, T., Blain, H., Petrovic, M., van der Cammen, T. J., Szczerbińska, K., Hartikainen, S., Kenny, R. A., Ryg, J., Eklund, P., Topinková, E., Mair, A., Laflamme, L., Thaler, H., Bahat, G., Gutiérrez-Valencia, M., Caballero-Mora, MA, Landi, F., Emmelot-Vonk, M. H., the EuGMS Task and Finish Group on  Fall-Risk-Increasing Drugs, Cherubini, A., Baeyens, J. P., Correa-Pérez, A., Gudmundsson, A., Marengoni, A., O’Mahony, D., Parekh, N., Pisa, F. E., Rajkumar, C., Wehling, M., Ziere, G., and the EuGMS Special Interest Group on Pharmacology

Published
2019
Full Text
View/download PDF

2. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.

Author

Wehling, M, Spencer, MJ, and Tidball, JG

Subjects
Muscle, Skeletal, Macrophages, Animals, Mice, Inbred mdx, Mice, Transgenic, Humans, Mice, Muscular Dystrophy, Duchenne, Disease Models, Animal, Creatine Kinase, Dystrophin, Transgenes, Nitric Oxide Synthase, Nitric Oxide Synthase Type I, Muscle Fibers, Skeletal, Non-programmatic, muscle, muscular dystrophy, nitric oxide synthase, macrophages, inflammation, Muscle, Skeletal, Inbred mdx, Transgenic, Muscular Dystrophy, Duchenne, Disease Models, Animal, Muscle Fibers, Developmental Biology, Biological Sciences, Medical and Health Sciences
Abstract

Dystrophin-deficient muscles experience large reductions in expression of nitric oxide synthase (NOS), which suggests that NO deficiency may influence the dystrophic pathology. Because NO can function as an antiinflammatory and cytoprotective molecule, we propose that the loss of NOS from dystrophic muscle exacerbates muscle inflammation and fiber damage by inflammatory cells. Analysis of transgenic mdx mice that were null mutants for dystrophin, but expressed normal levels of NO in muscle, showed that the normalization of NO production caused large reductions in macrophage concentrations in the mdx muscle. Expression of the NOS transgene in mdx muscle also prevented the majority of muscle membrane injury that is detectable in vivo, and resulted in large decreases in serum creatine kinase concentrations. Furthermore, our data show that mdx muscle macrophages are cytolytic at concentrations that occur in dystrophic, NOS-deficient muscle, but are not cytolytic at concentrations that occur in dystrophic mice that express the NOS transgene in muscle. Finally, our data show that antibody depletions of macrophages from mdx mice cause significant reductions in muscle membrane injury. Together, these findings indicate that macrophages promote injury of dystrophin-deficient muscle, and the loss of normal levels of NO production by dystrophic muscle exacerbates inflammation and membrane injury in muscular dystrophy.

Published
2001

4. Allgemeine Prinzipien der klinischen Pharmakologie

Author

Wehling, M., Steinbeck, Gerhard, editor, Paumgartner, Gustav, editor, Brandt, T., editor, Göke, B., editor, Greten, N., editor, Hiddemann, W., editor, Lode, H., editor, Mann, K., editor, Riess, H., editor, Risler, T., editor, Schattenkirchner, M., editor, Seeger, W., editor, and Wehling, M., editor

Published
2005
Full Text
View/download PDF

8. Pharmakologie und Pharmakotherapie

Author

Wagner, Th., Lenarz, Th., Wehling, M., Gattermann, N., Porschen, R., Rostock, M., Unger, C., Trautmann, Y., Heppt, W., Huether, G., Schäfer, M., Warnecke, J., Fehrs, W., Thiery, J., Seidel, D., Wößner, R., Sybrecht, G. W., Meister, R., Gleiter, C. H., Aul, C., Giagounidis, A., and Hiddemann, Wolfgang, editor

Published
2000
Full Text
View/download PDF

18. Tissue Biobanking

Author

Wehling, Martin, Wehling, M ( Martin ), Planas-Paz, Lara, Pauli, Chantal; https://orcid.org/0000-0001-9621-8511, Wehling, Martin, Wehling, M ( Martin ), Planas-Paz, Lara, and Pauli, Chantal; https://orcid.org/0000-0001-9621-8511

Published
2021

19. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

Author

Pazan, F, Petrovic, M, Cherubini, A, Onder, G, Cruz-Jentoft, AJ, Denkinger, M, van der Cammen, T, Stevenson, J M, Ibrahim, K, Rajkumar, C, Bakken, MS, Baeyens, JP, Crome, P, Frühwald, T, Gallaghar, P, Guðmundsson, A, Knol, W, O’Mahony, D, Pilotto, A, Rönnemaa, E, Serra-Rexach, JA, Soulis, G, van Marum, RJ, Ziere, Bert, Mair, A, Burkhardt, H, Neumann-Podczaska, A, Wieczorowska-Tobis, K, Fernandes, M, Gruner, H, Dallmeier, D, Beuscart, JB, Velde, N, Wehling, M, Pazan, F, Petrovic, M, Cherubini, A, Onder, G, Cruz-Jentoft, AJ, Denkinger, M, van der Cammen, T, Stevenson, J M, Ibrahim, K, Rajkumar, C, Bakken, MS, Baeyens, JP, Crome, P, Frühwald, T, Gallaghar, P, Guðmundsson, A, Knol, W, O’Mahony, D, Pilotto, A, Rönnemaa, E, Serra-Rexach, JA, Soulis, G, van Marum, RJ, Ziere, Bert, Mair, A, Burkhardt, H, Neumann-Podczaska, A, Wieczorowska-Tobis, K, Fernandes, M, Gruner, H, Dallmeier, D, Beuscart, JB, Velde, N, and Wehling, M

Abstract

Background: Frailty and adverse drug effects are linked in the fact that polypharmacy is correlated with the severity of frailty; however, a causal relation has not been proven in older people with clinically manifest frailty. Methods: A literature search was performed in Medline to detect prospective randomized controlled trials (RCTs) testing the effects of pharmacological interventions or medication optimization in older frail adults on comprehensive frailty scores or partial aspects of frailty that were published from January 1998 to October 2019. Results: Twenty-five studies were identified, 4 on comprehensive frailty scores and 21 on aspects of frailty. Two trials on comprehensive frailty scores showed positive results on frailty although the contribution of medication review in a multidimensional approach was unclear. In the studies on aspects related to frailty, ten individual drug interventions showed improvement in physical performance, muscle strength or body composition utilizing alfacalcidol, teriparatide, piroxicam, testosterone, recombinant human chorionic gonadotropin, or capromorelin. There were no studies examining negative effects of drugs on frailty. Conclusion: So far, data on a causal relationship between drugs and frailty are inconclusive or related to single-drug interventions on partial aspects of frailty. There is a clear need for RCTs on this topic that should be based on a comprehensive, internationally consistent and thus reproducible concept of frailty assessment.

Published
2021

21. Antikoagulation im Alter

Author

Harenberg, J., Bauersachs, R., Diehm, C., Lawall, H., Burkhardt, H., Gerlach, H., Darius, H., Völler, H., Rabe, E., and Wehling, M.

Published
2010
Full Text
View/download PDF

27. Deprescribing tool for STOPPFall (screening tool of older persons prescriptions in older adults with high fall risk) items

Author

Seppala, L. J., Petrovic, M., Jesper Ryg, Bahat, G., Topinkova, E., Szczerbińska, K., Cammen, T. J., Hartikainen, S., Ilhan, B., Landi, F., Morrissey, Y., Mair, A., Gutiérrez-Valencia, M., Emmelot-Vonk, M. H., Caballero Mora, M. A., Michael Denkinger, Crome, P., Jackson, S. H. D., Correa-Pérez, A., Knol, W., Soulis, G., Adalsteinn Gudmundsson, Ziere, G., Wehling, M., O’mahony, D., Antonio Cherubini, and Nathalie van der Velde

Subjects
screening, fall risk, Medicine and Health Sciences, Deprescribing tool, older persons prescriptions, STOPPFall
Abstract

Background: Health care professionals are often reluctant to deprescribe fall-risk-increasing drugs (FRIDs). Lack of knowledge and skills form a significant barrier. To support clinicians in the management of FRIDs and to facilitate the deprescribing process, a deprescribing tool was developed by a European expert group for STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) items. Methods: STOPPFall was created using an expert Delphi consensus process in 2019 and in 2020, 24 panellists from EuGMS SIG on Pharmacology and Task and Finish on FRIDs completed deprescribing tool questionnaire. To develop the questionnaire, a Medline literature search was performed. The panellists were asked to indicate for every medication class a possible need for stepwise withdrawal and strategy for withdrawal. They were asked in which situations withdrawal should be performed. Furthermore, panellists were requested to indicate those symptoms patients should be monitored for after deprescribing and a possible need for follow-ups. Results: Practical deprescribing guidance was developed for STOPPFall medication classes. For each medication class, a decision tree algorithm was developed including steps from medication review to symptom monitoring after medication withdrawal. Conclusion: STOPPFall was combined with a practical deprescribing tool designed to optimize medication review. This practical guide can help overcome current reluctance towards deprescribing in clinical practice by providing an up-to-date and straightforward source of expert knowledge.

Published
2020

48. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research

Author

Seppala, L.J., van der Velde, N., Masud, T., Blain, H, Petrovic, M. (Mirko), Cammen, T.J.M. (Tischa) van der, Szczerbińska, K. (K.), Hartikainen, S. (Sirpa), Kenny, R.A., Ryg, J., Eklund, P., Topinkova, E, Mair, A., Laflamme, L., Thaler, H., Bahat, G., Gutierrez-Valencia, M., Caballero-Mora, M.A., Landi, F., Emmelot-Vonk, M.H., Cherubini, A. (Antonio), Baeyens, J.P., Correa-Perez, A., Gudmundsson, A., Marengoni, A., O'Mahony, D., Parekh, N., Pisa, F.E., Rajkumar, C. (Chakravarthi), Wehling, M., Ziere, G. (Gijsbertus), Seppala, L.J., van der Velde, N., Masud, T., Blain, H, Petrovic, M. (Mirko), Cammen, T.J.M. (Tischa) van der, Szczerbińska, K. (K.), Hartikainen, S. (Sirpa), Kenny, R.A., Ryg, J., Eklund, P., Topinkova, E, Mair, A., Laflamme, L., Thaler, H., Bahat, G., Gutierrez-Valencia, M., Caballero-Mora, M.A., Landi, F., Emmelot-Vonk, M.H., Cherubini, A. (Antonio), Baeyens, J.P., Correa-Perez, A., Gudmundsson, A., Marengoni, A., O'Mahony, D., Parekh, N., Pisa, F.E., Rajkumar, C. (Chakravarthi), Wehling, M., and Ziere, G. (Gijsbertus)

Abstract

Falls are a major public health concern in the older population, and certain medication classes are a signifcant risk factor for falls. However, knowledge is lacking among both physicians and older people, including caregivers, concerning the role of medication as a risk factor. In the present statement, the European Geriatric Medicine Society (EuGMS) Task and Finish group on fall-risk-increasing drugs (FRIDs), in collaboration with the EuGMS Special Interest group on Pharmacology and the European Union of Medical Specialists (UEMS) Geriatric Medicine Section, outlines its position regarding knowledge dissemination on medication-related falls in older people across Europe. The EuGMS Task and Finish group is developing educational materials to facilitate knowledge dissemination for healthcare professionals and older people. In addition, steps in primary prevention through judicious prescribing, deprescribing of FRIDs (withdrawal and dose reduction), and gaps in current research are outlined in this position paper.

Published
2019
Full Text
View/download PDF

49. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research

Author

MS Geriatrie, Circulatory Health, Seppala, L. J., van der Velde, N., Masud, T., Blain, H., Petrovic, M., van der Cammen, T. J., Szczerbinska, K., Hartikainen, S., Kenny, R. A., Ryg, J., Eklund, P., Topinkova, E., Mair, A., Laflamme, L., Thaler, H., Bahat, G., Gutierrez-Valencia, M., Caballero-Mora, M. A., Landi, F., Emmelot-Vonk, M. H., Cherubini, A., Baeyens, J. P., Correa-Perez, A., Gudmundsson, A., Marengoni, A., O'Mahony, D., Parekh, N., Pisa, F. E., Rajkumar, C., Wehling, M., Ziere, G., MS Geriatrie, Circulatory Health, Seppala, L. J., van der Velde, N., Masud, T., Blain, H., Petrovic, M., van der Cammen, T. J., Szczerbinska, K., Hartikainen, S., Kenny, R. A., Ryg, J., Eklund, P., Topinkova, E., Mair, A., Laflamme, L., Thaler, H., Bahat, G., Gutierrez-Valencia, M., Caballero-Mora, M. A., Landi, F., Emmelot-Vonk, M. H., Cherubini, A., Baeyens, J. P., Correa-Perez, A., Gudmundsson, A., Marengoni, A., O'Mahony, D., Parekh, N., Pisa, F. E., Rajkumar, C., Wehling, M., and Ziere, G.

Published
2019

50. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research

Author

Seppala, LJ, Velde, N, Masud, T, Blain, H, Petrovic, M, van der Cammen, T.J.M., Szczerbinska, K, Hartikainen, S, Kenny, RA, Ryg, J, Eklund, P, Topinkova, E, Mair, A, Laflamme, L, Thaler, H, Bahat, G, Gutierrez-Valencia, M, Caballero-Mora, MA, Landi, F, Emmelot-Vonk, MH, Cherubini, A, Baeyens, JP, Correa-Perez, A, Gudmundsson, A, Marengoni, A, O'Mahony, D, Parekh, N, Pisa, FE, Rajkumar, C, Wehling, M, Ziere, Bert, Seppala, LJ, Velde, N, Masud, T, Blain, H, Petrovic, M, van der Cammen, T.J.M., Szczerbinska, K, Hartikainen, S, Kenny, RA, Ryg, J, Eklund, P, Topinkova, E, Mair, A, Laflamme, L, Thaler, H, Bahat, G, Gutierrez-Valencia, M, Caballero-Mora, MA, Landi, F, Emmelot-Vonk, MH, Cherubini, A, Baeyens, JP, Correa-Perez, A, Gudmundsson, A, Marengoni, A, O'Mahony, D, Parekh, N, Pisa, FE, Rajkumar, C, Wehling, M, and Ziere, Bert

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results